Harbour BioMed has established a robust pipeline in oncology and immunology since the company was established in early 2017. The current portfolio includes four clinical-stage in-licensed compounds and a rapidly emerging set of therapeutics coming from its internal discovery efforts as well as co-discovery/development collaborations with academic institutions and biopharmaceutical companies.

Harbour BioMed's Global Product Pipeline


Harbour BioMed's Discovery Pipeline

友情链接:ag赌场  澳门皇家赌场网站  皇家真人游戏下载  宝马城娱乐bm777  澳门葡京app下载  大发dafa888  亿万先生  永利棋牌登录